Linfoma Cutáneo de Células B de la Zona Marginal, una patología al alza

  1. I. López de Cenarruzabeitia 1
  2. C. de la Cuesta de la Llave 1
  3. E Pastor Fuente 1
  4. B. Rodríguez Sanz 1
  5. D. González González 1
  6. C. Benito Fernández 1
  7. C Pacheco Sánchez 1
  1. 1 Hospital Universitario Río Hortega. Valladolid
Revista:
Cirugía Andaluza

ISSN: 2695-3811,  1130-3212

Año de publicación: 2023

Volumen: 34

Número: 1

Páginas: 31-44

Tipo: Artículo

DOI: 10.37351/2023341.5 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Cirugía Andaluza

Resumen

El hecho de que un agente infeccioso pueda iniciar una inflamación crónica y constituir el motivo esencial en la transformación de los linfocitos B y la posterior linfomagénesis ha recuperado interés en la comunidad científica en los últimos años. Presentamos un Caso Clínico con el fin de reflejar la necesidad de concienciación en la consideración del Linfoma Linfocitos B Primario Cutáneo de la Zona Marginal (PCMZL) como posible diagnóstico dentro de lesiones indolentes de evolución tórpida, con buen pronóstico, y que actualmente han mostrado una mayor incidencia en la edad pediátrica y juvenil. El paciente presentaba antecedentes de infección faringotomsilar recurrente con una fuerte asociación con el desarrollo de PCMZL. Es posible, al igual que se ha demostrado la asociación de la etiopatogenia en algunos casos de PCMZL con la infección por Borrelia Burgdorferi y otras infecciones bacterianas, que la infección crónica por Streptococcus Pyogenes pudiera inducir la aparición de una transformación de los linfocitos B de la zona marginal en una célula neoplásica, desarrollando así un linfoma de células B de la zona marginal. Este proceso de agresión crónica por un antígeno (estreptolisina O), produciría una selección monoclonal de células plasmáticas que serían las responsables de la producción de Ig/estreptolisina O, esta estirpe monoclonal sufriría una transformación neoplásica a lo largo de esta estimulación sostenida, logrando escapar a mecanismos de regulación, y manteniendo títulos de ASLO continuamente elevados, como en el caso que presentamos.

Referencias bibliográficas

  • Bende RJ, van Maldegem F, van Noesel CJ. ‘Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas’. Haematologica. 2009 Aug;94(8):1109-23. doi: 10.3324/haematol.2009.005983. Epub 2009 Jul 16. PMID: 19608670; PMCID: PMC2719034.
  • Dumont M, Battistella M, Ram-Wolff C, Bagot M, de Masson A. ‘Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives’. Cancers (Basel). 2020 Jun 8;12(6):1497. doi: 10.3390/ cancers12061497. PMID: 32521744; PMCID: PMC7352758.
  • Cerutti A, Cols M, Puga I. ‘Marginal zone B cells: virtues of innate-like antibodyproducing lymphocytes’. Nat Rev Immunol. 2013 Feb;13(2):118-32. doi: 10.1038/ nri3383. PMID: 23348416; PMCID: PMC3652659.
  • Abbas O, Mahalingam M. ‘The grenz zone’. Am J Dermatopathol. 2013 Feb;35(1):83-91. doi: 10.1097/DAD.0b013e31824feb4e. PMID: 23348142.
  • Hristov AC, Tejasvi T, Wilcox RA. ‘Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management’. Am J Hematol. 2020 Aug 20. doi: 10.1002/ajh.25970. Epub ahead of print. PMID: 32815650.
  • Lee CL, Lee IS, Jung SG. ‘A case of nodal marginal zone B-cell lymphoma of the lower eyelid’. Arch Craniofac Surg. 2020 Aug;21(4):249-252. doi: 10.7181/ acfs.2020.00241. Epub 2020 Aug 20. PMID: 32867415; PMCID: PMC7463130.
  • Gibson SE, Swerdlow SH. ‘How I Diagnose Primary Cutaneous Marginal Zone Lymphoma’. Am J Clin Pathol. 2020 Sep 8;154(4):428-449. doi: 10.1093/ajcp/ aqaa116. PMID: 32808967.
  • Dobos G, Miladi M, Michel L, Ram-Wolff C, Battistella M, Bagot M, de Masson A. ‘Recent advances on cutaneous lymphoma epidemiology’. Presse Med. 2022 Jan 11;51(1):104108. doi: 10.1016/j.lpm.2022.104108. Epub ahead of print. PMID: 35026392.
  • Bradford PT, Devesa SS, Anderson WF, Toro JR. ‘Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases’. Blood. 2009 May 21;113(21):5064-73. doi: 10.1182/blood-2008-10-184168. Epub 2009 Mar 11. PMID: 19279331; PMCID: PMC2686177.
  • Dores GM, Anderson WF, Devesa SS. ‘Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system’. J Clin Oncol. 2005 Oct 1;23(28):7246- 8. doi: 10.1200/JCO.2005.03.0395. PMID: 16192622.
  • Wilson LD, Hinds GA, Yu JB. ‘Age, race, sex, stage, and incidence of cutaneous lymphoma’. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):291-6. doi: 10.1016/j. clml.2012.06.010. PMID: 23040434; PMCID: PMC3475508.
  • Hamada T, Iwatsuki K. ‘Cutaneous lymphoma in Japan: a nationwide study of 1733 patients’. J Dermatol. 2014 Jan;41(1):3-10. doi: 10.1111/1346-8138.12299. PMID: 24438138.
  • Han JH, Ko YH, Kang YK, Kim WS, Kim YJ, Kim I, Kim HJ, Min SK, Park CK, Park CS, Shin BK, Yang WI, Oh YH, Lee JS, Lee J, Lee TH, Lee H, Lee HJ, Jeon YK, Cha HJ, Choi YD, Kim CW; ‘Hematopathology Study Group of the Korean Society of Pathologists. Characteristics of Cutaneous Lymphomas in Korea According to the New WHO-EORTC Classification: Report of a Nationwide Study’. Korean J Pathol. 2014 Apr;48(2):126-32. doi: 10.4132/KoreanJPathol.2014.48.2.126. Epub 2014 Apr 28. PMID: 24868225; PMCID: PMC4026803.
  • Saunes M, Nilsen TI, Johannesen TB. ‘Incidence of primary cutaneous T-cell lymphoma in Norway’. Br J Dermatol. 2009 Feb;160(2):376-9. doi: 10.1111/j.1365- 2133.2008.08852.x. Epub 2008 Sep 19. PMID: 18808419.
  • Abbott RA, Aldridge C, Dojcinov S, Piguet V. ‘Incidence of primary cutaneous T-cell lymphoma in Wales’. Br J Dermatol. 2013 Dec;169(6):1366-7. doi: 10.1111/ bjd.12516. PMID: 23855741.
  • Assaf C, Dobos G, Zech IM, Doess A, Hibbe T, Jadasz JJ. ‘Care structure of patients with mycosis fungoides and Sézary syndrome in Germany Care research based on SHI claims data’. J Dtsch Dermatol Ges. 2022 May;20(5):643- 651. doi: 10.1111/ddg.14725. Epub 2022 May 2. PMID: 35499207.
  • Delsol G. Classification OMS 2008 des lymphomes [The 2008 WHO lymphoma classification]. Ann Pathol. 2008 Nov;28 Spec No 1(1):S20-4. French. doi: 10.1016/j.annpat.2008.09.002. Epub 2008 Oct 15. PMID: 18984289.
  • Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, d'Incan M, Rouanet J, et al.; French Study Group on Cutaneous Lymphomas (GFELC). ‘Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry’. Br J Dermatol. 2021 Jun;184(6):1059-1067. doi: 10.1111/bjd.19644. Epub 2020 Nov 29. PMID: 33131055.
  • Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. ‘The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas’. Blood. 2019 Apr 18;133(16):1703-1714. doi: 10.1182/ blood-2018-11-881268. Epub 2019 Jan 11. Erratum in: Blood. 2019 Sep 26;134(13):1112. PMID: 30635287; PMCID: PMC6473500.
  • Bomze D, Sprecher E, Goldberg I, Samuelov L, Geller S. ‘Primary Cutaneous B-Cell Lymphomas in Children and Adolescents: A SEER Population-Based Study’. Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e1000-e1005. doi: 10.1016/j.clml.2021.07.021. Epub 2021 Jul 25. PMID: 34417159.
  • Ghazawi, F.M., Netchiporouk, E., Rahme, E., Tsang, M., Moreau, L., Glassman, S., Provost, N., Gilbert, M., Jean, S.-E., Pehr, K., Sasseville, D. and Litvinov, I.V. (2017), ‘Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy’. Cancer, 123: 3550-3567. https://doi.org/10.1002/cncr.30758
  • Henry, K.A., Wiese, D., Maiti, A. et al. ‘Geographic clustering of cutaneous T-cell lymphoma in New Jersey: an exploratory analysis using residential histories’. Cancer Causes Control 32, 989–999 (2021). https://doi.org/10.1007/s10552- 021-01452-y
  • Litvinov, I.V., Tetzlaff, M.T., Rahme, E., Habel, Y., Risser, D.R., Gangar, P., Jennings, M.A., Pehr, K., Prieto, V.G., Sasseville, D. and Duvic, M. (2015), ‘Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries’. Cancer, 121: 1993-2003. https://doi. org/10.1002/cncr.29301
  • Moreau JF, Buchanich JM, Geskin JZ, Akilov OE, Geskin LJ. ‘Non-random geographic distribution of patients with cutaneous T-cell lymphoma in the Greater Pittsburgh Area’. Dermatol Online J. 2014 Jul 15;20(7):13030/ qt4nw7592w. PMID: 25046454.
  • Clough L, Bayakly AR, Ward KC, Khan MK, Chen SC, Lechowicz MJ, Flowers CR, Allen PB, Switchenko JM. ‘Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia’. Cancer. 2020 Apr 15;126(8):1700-1707. doi: 10.1002/cncr.32665. Epub 2020 Jan 14. PMID: 31943154; PMCID: PMC7328827.
  • Malachowski SJ, Moy A, Messina J, Chen YA, Sun J, Sokol L, Seminario-Vidal L. ‘Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns’. J Am Acad Dermatol. 2022 Jan;86(1):186-188. doi: 10.1016/j.jaad.2021.01.041. Epub 2021 Jan 19. PMID: 33476732.
  • Biernat MM, Wróbel T. ‘Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment’. Int J Mol Sci. 2021 Jul 9;22(14):7372. doi: 10.3390/ijms22147372. PMID: 34298992; PMCID: PMC8305669.
  • Chen ST, Barnes J, Duncan L. ‘Primary cutaneous B-cell lymphomasclinical and histopathologic features, differential diagnosis, and treatment’. Semin Cutan Med Surg. 2018 Mar;37(1):49-55. doi: 10.12788/j.sder.2018.014. PMID: 29719020.
  • Hope CB, Pincus LB. ‘Primary Cutaneous B-cell Lymphomas’. Clin Lab Med. 2017 Sep;37(3):547-574. doi: 10.1016/j.cll.2017.05.009. PMID: 28802500.
  • Goyal A, LeBlanc RE, Carter JB. ‘Cutaneous B-Cell Lymphoma’. Hematol Oncol Clin North Am. 2019 Feb;33(1):149-161. doi: 10.1016/j.hoc.2018.08.006. PMID: 30497672.
  • Ronchi A, Sica A, Vitiello P, Franco R. ‘Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas’. Clin Cosmet Investig Dermatol. 2021 Mar 8;14:231-239. doi: 10.2147/CCID.S277667. PMID: 33727844; PMCID: PMC7954031.
  • Golling P, Cozzio A, Dummer R, French L, Kempf W. ‘Primary cutaneous B-cell lymphomas clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome’. Leuk Lymphoma. 2008 Jun;49(6):1094-103. doi: 10.1080/10428190802064925. PMID: 18569636.
  • Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss FM, Geskin LJ, Schwartz LH, Horwitz SM, Guitart J, Zic J, Kim YH et al. ‘Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC’. Blood. 2021 Nov 10:blood.2021012057. doi: 10.1182/blood.2021012057. Epub ahead of print. PMID: 34758074.
  • Lima M. ‘Cutaneous primary B-cell lymphomas: from diagnosis to treatment’. An Bras Dermatol. 2015 Sep-Oct;90(5):687-706. doi: 10.1590/abd1806- 4841.20153638. PMID: 26560215; PMCID: PMC4631235.
  • Oschlies I, Wehkamp U. ‘Cutaneous B cell lymphomas: standards in diagnostic and clinical work-up. Hints, pitfalls and recent advances’. Histopathology. 2022 Jan;80(1):184-195. doi: 10.1111/his.14556. PMID: 34958501.
  • Jothishankar B, Di Raimondo C, Mueller L, Zain J, Parekh V, Abdulla F. ‘Primary cutaneous marginal zone lymphoma treated with doxycycline in a pediatric patient’. Pediatr Dermatol. 2020 Jul;37(4):759-761. doi: 10.1111/pde.14165. Epub 2020 Apr 23. PMID: 32323885.
  • Oertel M, Elsayad K, Weishaupt C, Steinbrink K, Eich HT. ‘De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma’. Strahlenther Onkol. 2020 Feb;196(2):126-131. English. doi: 10.1007/s00066-019-01541-7. Epub 2019 Nov 22. PMID: 31758232.
  • Xu Z, Margolskee E, Villasenor-Park J, Rubin AI, Khurana MC. ‘A healthy 16-year-old boy presenting with multifocal asymptomatic subcutaneous nodules’. Pediatr Dermatol. 2022 Jan;39(1):e8-e10. doi: 10.1111/pde.14854. PMID: 35106821.
  • Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, et al. . ‘CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)’. Ann Hematol. 2011 Apr;90(4):401-8. doi: 10.1007/s00277-010-1083-1. Epub 2010 Sep 25. PMID: 2087200
  • Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R. ‘Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study’. J Clin Oncol. 2001 Aug 15;19(16):3602-10. doi: 10.1200/ JCO.2001.19.16.3602. PMID: 11504742.
Fuente de los datos: Dialnet